Pharmacokinetics of caffeine administered in a time-release versus regular tablet form by Adam M Gonzalez et al.
POSTER PRESENTATION Open Access
Pharmacokinetics of caffeine administered in a
time-release versus regular tablet form
Adam M Gonzalez, Jay R Hoffman, Adam J Wells, Gerald T Mangine, Jeremy R Townsend, Adam R Jajtner,
Ran Wang, Amelia A Miramonti, Gabriel J Pruna, Michael B LaMonica, Jonathan D Bohner, Mattan W Hoffman,
Leonardo P Oliveira, David H Fukuda, Maren S Fragala, Jeffrey R Stout*
From The Eleventh International Society of Sports Nutrition (ISSN) Conference and Expo
Clearwater Beach, FL, USA. 20-21 June 2014
Background
Caffeine has been associated with enhancing the ability to
perform mental tasks and elevate feelings of energy, how-
ever, a single dose of caffeine typically induces only 90-120
minutes of increased alertness and is often associated with
an acute “crash” state following its metabolism. The nature
of formulation can directly influence the rate and extent of
absorption following oral administration. Time-release
caffeine supplements have been developed to prolong the
effects of caffeine. The purpose of this study was to com-
pare the plasma caffeine pharmacokinetics following
ingestion of a time-release caffeine capsule (TR-CAF) to
an equivalent dose of a regular caffeine capsule (CAF) and
a placebo (PL) over an 8-hour period.
Methods
Ten healthy males (25.9 ± 3.2 y; 181.3 ± 8.2 cm; 92.9 ±
9.9 kg; 13.3 ± 3.6 % body fat) who regularly consume
caffeine volunteered to participate in this double-blind,
placebo-controlled, cross-over study. Participants were
randomized into three experimental trials: Ingestion of
EnergizeTM; CAF; and PL. The EnergizeTM supplement
contained 194 mg time-release caffeine and CAF con-
tained the equivalent amount of regular caffeine. PL con-
tained rice flour only. Blood draws occurred at baseline
and at every hour during the 8-hour period. Participants
were provided a standardized breakfast and lunch and
were permitted to drink water ad libitum. Plasma caffeine
concentrations were quantified using high performance
liquid chromatography (HPLC). Consent to publish the
results was obtained from all participants.
Results
Plasma caffeine concentrations for both caffeine supple-
ments were significantly greater than PL over the
8-hour study duration. CAF rapidly reached peak plasma
caffeine concentration (2.40 ± 0.40 mg•L-1) at 3 hours
following ingestion, while TR-CAF reached peak plasma
caffeine concentration (1.88 ± 0.46 mg•L-1) at 6 hours
following ingestion. Plasma caffeine concentrations were
significantly greater (p<0.05) in CAF compared to
TR-CAF during hours 2-5. However, plasma caffeine
concentrations were significantly greater (p=0.042) in
TR-CAF compared to CAF at hour 8. AUC analysis
showed plasma caffeine concentrations for CAF were
significantly greater than TR-CAF for hours 1-4
(p<0.0001) and over the 8-hour study duration (p<0.001).
Conclusion
The results suggest that the rate of caffeine absorption
following TR-CAF was slower and more sustained as
compared to CAF over 8 hours following ingestion
which may prolong the effects of caffeine and limit the
acute “crash” state.
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